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Abstract
We sought to investigate the prognostic significance of prodromal angina (PA) in unselected patients with ST-segment elevation
myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) and its additive predictive value to the
GRACE score.
We prospectively enrolled 3015 consecutive STEMI patients undergoing PPCI. Patients were divided in 2 groups according to the
presence or absence of PA. Multivariable Cox regression was used to establish the relation to 2-year cardiac mortality of PA.
Themean age of the study populationwas 68 (±14) years; 2178 patients (72%)weremale. During follow-up, 395 (13%) patients died
with 278 of these (9.2%) suffering from cardiac mortality. Kaplan-Meier estimates showed a survival rate of 95% and 87% for patients
with PA and no PA, respectively (log rank test<0.001). After multivariable analysis, patients with PA had still a lower risk of 2 years’
cardiac mortality compared with patients without PA (adjusted hazard ratio=0.50; 95% confidence interval [CI] 1.06–1.81, P= .001).
Evaluation of net reclassification improvement showed that reclassification improved by 0.16% in case patients, whereas classification
worsened in control patients by 1.08% leading to a net reclassification improvement of 0.93% (95% CI: 0.98, 0.88).
In patients with STEMI undergoing PPCI the presence of PA is independently associated with a lower risk of 2-year cardiac
mortality. However, the incorporation of this variable to the GRACE score slightly worsened the classification of risk. Accordingly, it
seems unlikely that the evaluation of PA may be useful in clinical practice.
Abbreviations: DES = drug-eluting stent, ECG = electrocardiogram, GP IIb/IIIa = glycoprotein IIb/IIIa, GRACE = Global Registry
of Acute Coronary Events, LVEF= left ventricular ejection fraction, MI=myocardial infarction, NRI= net reclassification improvement,
PA = prodromal angina, PPCI = primary percutaneous coronary intervention, SD = standard deviation, STEMI = ST elevation
myocardial infarction, TIMI = thrombolysis in myocardial infarction.
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In patients with ST-segment elevation myocardial infarction
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has emerged as the preferred reperfusion therapy to achieve early
reperfusion, limit the infarct size, and ultimately reduce short and
long-term fatality rates for MI.[1,2]
Despite obtaining a coronary flow restoration in most of the
cases, mechanisms that determine the extent of myocardial
damage are multifactorial and poorly understood. They mainly
comprise the area at risk, the total ischemic time, reperfusion
injury, microembolization, and microvascular obstruction.[3] It
has been suggested that prodromal angina (PA) related to brief
episode of myocardial ischemia before index MI (the so-called
ischemic preconditioning) may contribute to limit the final infarct
size.[4,5] Two recent studies[6,7] prospectively enrolling a small
series of STEMI patients undergoing PPCI have shown that PA is
independently associated with an increases myocardial savage
and final infarct size as assessed with cardiac magnetic resonance.
However, if these findings translate into an independent
prognostic role of PA in the clinical setting of PPCI has not
been established yet. Furthermore, whether the addition of PA
to a current recommended GRACE risk score[8] improves the
classification of risk has not been studied yet.
Therefore, the objectives of the present study were: to
investigate the association between PA and 2-year cardiovascular
mortality in an unselected cohort of STEMI patients undergoing
Ghetti et al. Medicine (2018) 97:37 MedicinePPCI and to evaluate its additive predictive value to the clinical
risk model.2. Material and methods
The present prospective cohort study (conceived in accordance
with the principles of the most recent revision of the Declaration
of Helsinki) was based on the database of one (S. Orsola-
Malpighi Hospital) of the 2 centralized PPCI centers of the
“Bologna STEMI hub and spoke network."[9,10] This prospective
database contains demographic information along with compre-
hensive clinical, electrocardiogram (ECG), procedural, and
outcome data from STEMI patients treated with PPCI at the
center’s catheterization laboratory. The registry started in 2003
and was approved by the hospital’s Ethics Committee. For the
purpose of the present study, we include consecutive out-of-
hospital STEMI patients treated with PPCI from January 1, 2003
to December 31, 2015. We excluded patients with missing data
and those with coma at presentation owing to the difficulty of
ascertaining the presence or not of PA.
STEMI was defined as significant ST-elevation (in 2 adjacent
leads and 0.1mV in leads I–III, aVF, aVL, V4–V6, and 0.2mV in
leads V1–V3) or in presence of STEMI-equivalent, namely new-
onset (or presumably new) left bundle branch block, posterior
STEMI and ST-T de Winter complex.[11] Stenosis ≥50% in the
lumen of left main artery or ≥70% in ≥1 of other major
epicardial vessels or their main branches was considered
significant. The culprit lesion was defined as the lesion with
the highest degree of stenosis or in the presence of thrombolysis in
myocardial infarction (TIMI) flow grade <3 or angiographic
signs of endoluminal thrombi and/or plaque rupture. Coronary
thrombus was defined as an intraluminal filling defect or an area
of contrast staining within the coronary lesion. Plaque rupture
was defined by the presence of a small crater or visible intimal
flap. In case of TIMI flow<2, thrombotic coronary occlusion was
defined on the basis of morphology and lack of collateral vessels.
Percutaneous coronary intervention (PCI) was mainly performed
within 12hours of the self-reported onset of symptoms. Patients
with symptom onset-to-STEMI diagnosis time interval between
12 and 24hours were enrolled only in case of evident ongoing
myocardial ischemia. Before PCI execution at the time of
diagnosis, all patients received aspirin (250mg i.v.) and heparin
(5000 IU i.v). Vascular access, use of platelet glycoprotein IIb/IIIa
agents, manual thrombectomy, and type of stent were at
operator’s discretion. After PCI, P2Y12 inhibitors were adminis-
tered according to current guidelines.
Cardiac arrest was defined as cardiac arrest occurring before
revascularization and requiring resuscitation procedures, (e.g.,
ventilation, chest compression, defibrillation).
PA was defined as ≥1 episodes of angina (Canadian
cardiovascular Sociaty class ≥1) up to 3 months before the
index episode, based on previous results.[7,12]
Study endpoint was cardiac mortality at 2-year follow-up.
Cardiac death was defined as death from cardiac cause, sudden
death, or any death without another known cause. In-hospital re-
MI was defined as the recurrence of typical clinical symptoms and
new ECG changes with an increase of MB Creatin-Kinase (MB-
CK) above ≥ 50% of the previous levels. Out-of-hospital data
concerning vital status of patients and cause of death were
obtained by telephone interviews or independently from the
Emilia-Romagna Regional Health Agency through the analysis
of the Hospital Discharge Records and the Municipal Civil
Registries, thus relying on treating physician’s diagnosis.2
Categorical data are expressed as proportions and continuous
variables reported as mean (±SD) or medians medians (25th–75th
percentiles). Patients were divided into 2 groups: those with no
PA and patients with PA. For comparisons between groups, the
x2 test was used for categorical variables. Continuous variables
were tested for normal distribution and tested using Student t or
Mann-Whitney tests as appropriate.
The Kaplan-Meyer method was used to analyze the
occurrence of events during follow-up. Study groups were
compared by means of the log-rank Cox-Mantel test. Patients
were censored at 2 years or at the time of the last contact. The
relation to 2-year cardiac mortality of PA was investigated with
the use of multivariable Cox regression model adjusted for
variable selected at univariable analysis (P< .1). Thus, the
following variables were entered in a multivariable backward
selection: age, sex, smoking status, hypercholesterolemia,
diabetes, hypertension, family history of coronary artery
disease, previousMI, previous stroke, peripheral artery disease,
systolic blood pressure and heart rate on admission, anterior
MI, Killip class, cardiac arrest, creatinine levels on admission,
left ventricle ejection fraction (LVEF), radial access, multivessel
disease, GP IIb/IIIa inhibitors, pre and post TIMI flow grade,
pain to balloon interval, and PA. Proportional hazard
assumption was checked by Shoenfeld tests. Model discrimina-
tion was assessed using the Harrell C-index.[13] and confidence
intervals were calculated using bootstraps estimation. Calibra-
tion was evaluated by the Groennesby and Borgan test
approach for survival data,[14] with a x2 ≥ 20 (P< .01)
indicating poor calibration.
The additional contribution of PA to the GRACE risk score for
prediction of study endpoint was evaluated in terms of
classification accuracy measuring the continuous net reclassifica-
tion improvement (NRI) as previously described.[15] Confident
intervals were calculated using bootstraps estimation. A P value
<.05 in the 2-tailed tests was considered significant. All analyses
were performed with STATA 14.0 software (STATA Corpora-
tion, College Station, TX).3. Results
During the study period, 3278 of hospital STEMI patients
were treated with PPCI and enrolled in the prospective
dataset of our Institution. For the purpose of the present study,
263 patients were excluded because of missing values and/or
coma at admission (Fig. 1). Thus, the final study cohort
comprises 3015 of hospital STEMI patients undergoing primary
angioplasty.
Baseline characteristics are listed in Table 1. The mean age of
the study population was 68 (± 14) years; 2178 patients (72%)
were male. Among the study cohort, 685 (23%) had PA before
the index MI. Patients with PA were generally younger than
patients with no PA. They were more likely to be male and had a
lower prevalence of hypertension, previous MI, and previous
PCI. Patients with PA had a better clinical profile in terms of Killip
class, LVEF, and pre-TIMI flow grade. They were more likely to
receive radial access, drug-eluting stent (DES) implantation, and
thrombus aspiration.
Overall, the rate of in-hospital mortality was 4.6% (Table 2).
All deaths, but one (sepsis), were from cardiac origin. Patients
with PA had a statistically significant lower rate of cardiac
mortality than patients without PA (2.3%vs. 5.3%, respectively).
There were no statistically significant differences in the rate of in
hospital re-MI between the study groups (Table 2).
Table 1
Baseline characteristics.
Variable All patients No prodromal angina Prodromal angina
PNo. of patients n=3015 n=2330 n=685
Age, years, mean±SD 68±14 68±14 66±13 <.001
Male sex, no. (%) 2178 (72) 1657 (71) 521 (76) .011
Medical history
Previous MI, no. (%) 515 (17) 434 (18) 81 (12) <.001
Previous PCI, no. (%) 353 (12) 302 (13) 51 (8) <.001
Previous coronary bypass, no. (%) 69 (2.3) 55 (2.4) 14 (2.0) .626
Previous stroke/AIT, no. (%) 159 (5) 128 (6) 31 (5) .319
Peripheral artery disease, no. (%) 315 (10) 244 (11) 71 (10) .936
Risk factors
Diabetes, no. (%) 608 (20) 490 (21) 118 (17) .029
Hypercholesterolemia, no. (%) 192 (64) 1467 (63) 454 (66) .113
Hypertension, no. (%) 2099 (70) 1665 (71) 434 (63) <.001
Smokers, no. (%) 1966 (65) 1501 (64) 465 (68) .09
Family-history of CAD, no. (%) 971 (32) 744 (32) 227 (33) .552
Presenting characteristics
Anterior MI, no. (%) 1466 (49) 1114 (48) 352 (51) .1
Systolic BP, mmHg, mean±SD 128±30 128±30 129±29 .530
Heart rate, pulse/min, mean±SD 76±19 76±19 76±18 .8214
Cardiac arrest, no. (%) 115 (38) 94 (4.0) 21 (3.0) .245
Killip class >2, no. (%) 423 (14) 357 (15) 66 (10) <.001
Creatinine, mg/dL, mean±SD 1.13±0.7 1.14±0.68 1.12±0.78 .58
LVEF, mean±SD 49±11 49±12 51±12 .001
Procedure and medications
Radial access, no. (%) 1157 (39) 786 (34) 371 (54) <.001
Multivessel disease, no. (%) 1515 (50) 1146 (49) 369 (54) .031
Pre-TIMI flow grade <2, no. (%) 2374 (79) 1863 (80) 511 (75) .031
Post-TIMI flow grade <2, no. (%) 115 (38) 92 (3.9) 23 (3.4) .478
DES, no. (%) 476 (16) 336 (14) 140 (70) <.001
Thrombus aspiration, no. (%) 660 (22) 483 (24) 177 (26) .004
P2Y12 inhibitor, no. (%) 2879 (96) 2217 (95) 662 (97) .098
GP IIb/IIIa 2203 (73) 1710 (73) 493 (72) .402
Total ischemic time, min (25th–75th) 180 (120–295) 179 (121–297) 183 (120–290) .97
BP=blood pressure, DES=drug-eluting stent, LVEF= left ventricular ejection fraction, MI=myocardial infarction, PCI= percutaneous coronary intervention, TIMI= thrombolysis in myocardial infarction.
Figure 1. Study flow chart.




Variable All patients No Prodromal angina Prodromal angina
PNo. of patients n=3015 n=2330 n=685
In-hospital outcome
All-cause mortality, no. (%) 140 (4.6) 124 (5.3) 16 (2.34) .001
Cardiac mortality, no. (%) 139 (4.6) 123 (5.3) 16 (2.34) .001
Re- myocardial infarction, no. (%) 55 (1.8) 37 (1.6) 18 (2.6) .074
Two-year outcome
∗
All-cause mortality, no. (%) 395 (13) 350 (15) 45 (6.6) <.001
Cardiac mortality, no. (%) 278 (9.2) 251 (11) 27 (4) <.001
Fatal myocardial infarction 96 (35%) 86 (34.26) 10 (37.0) .77
Re-myocardial infarction 311 (10.3) 238 (10.2) 73 (10.6) .74
∗
Patients with complete follow-up=2981 (98.87%).
Table 3
Independent predictors of 2-year cardiac mortality. Multivariable
Cox regression analysis.
Variable HR (95% CI) P
Age, years, 1.05 (1.04–1.07) <.001
Diabetes 1.39 (1.06–1.81) .016
Systolic BP, mmHg 0.99 (0.99–1.00) .008
Cardiac arrest 1.68 (1.01–2.79) .045
Killip class >2 2.22 (1.65–2.97) <.001
Creatinine, mg/dL 1.16 (1.03–1.29) .012
LVEF 0.94 (0.93–0.95) <.001
Radial access 0.64 (0.46–0.89) .009
DES 0.41 (0.25–0.70) <.001
GP IIb/IIIa 0.71 (0.55–0.93) .009
Prodromal angina 0.50 (1.06–1.81) .001
BP=bloood pressure, DES=drug-eluting stent, HR=hazard ratio, LVEF= left ventricular ejection
fraction.
Figure 2. Kaplan-Meier estimates for 2 year cardiac
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During amedian follow-up of 2 years (only 34 [1.1%], patients
had incomplete follow-up with a minimum value of 286 days),
395 patients died (13%). Of these, 278 patients (9.2%) suffered
from cardiac mortality. The rates of both fatal and non-fatal re-
MI were comparable (Table 2).
Kaplan-Meier estimates showed a survival rate of 95% and
87% for patients with PA and no PA, respectively (Fig. 2, log rank
test<0.001).
After univariable and multivariable analysis, patients with PA
had still a lower risk of 2 years cardiac mortality compared with
patients without PA (adjusted hazard ratio [HR]=0.50; 95%
confidence interval [CI] 1.06–1.81, P= .001) (Table 3). The
model showed good discrimination power (Harrell C=0.876,
95% CI 0.858–0.897) and good calibration (Groennesby and
Borgan x2=8.065; P= .153).
Evaluation of NRI showed that reclassification improved by
0.16% in case patients, whereas classification worsened in
control patients by 1.08% leading to a NRI of0.93% (95%CI:
0.98, 0.88).mortality in patients with PA and those without.
Ghetti et al. Medicine (2018) 97:37 www.md-journal.com4. Discussion
The main findings of the present study enrolling 3015 unselected
STEMI patients undergoing PPCI are as follows: patients with PA
have a lower risk of 2-year cardiac mortality compared to those
without; the incorporation of PA into the GRACE score does not
improve classification of risk.
In acute MI with ST segment elevation the definite treatment is
to rapidly restore coronary blood flow and myocardial perfusion
with the objective of reducing infarct size and improve
outcome.[1,2] The size of the scar is directly associated with
duration of myocardial ischemia. Previous studies have shown
that PA leads to a more rapid reperfusion and smaller infarct size
in patients with acute myocardial infarction treated with
thrombolysis[16] with a mechanism not fully understood but
likely involving ischemic preconditioning.[17,18] In the setting of
PPCI, 2 recent studies prospectively enrolling a small series of
STEMI have shown that PA is independently associated with an
increase myocardial savage and smaller final infarct size as
assessed with cardiac magnetic resonance.[6,7] However, if these
findings translate into a favorable effect of PA on long-term
prognosis has not been established, yet.
In the present study, enrolling a large cohort of STEMI patients
undergoing PPCI, we show that those experiencing episode of
angina up to 3 months before the index episode have a lower risk
of cardiac mortality. Patients with PA have a better risk profile in
terms of some characteristics such as diabetes and DES utilization
and this could be partly account for its prognostic role. However,
the strength of this finding relies on a comprehensive multivari-
able adjustment including also the LVEF, a main prognosticators
of long-term prognosis after MI.[19] Of note, the rates of MI
during follow-up between the study groups were comparable
confirming that PA exercises its protective role reducing both the
risk of life-threatening arrhythmias[20,21] and the risk of heart
failure[22] in keeping with the theory that ischemic precondition-
ing reduces the infarct size and favors the post-ischemic recovery
of global ventricular function.[23] In particular, the risk of life-
threatening arrhythmias remains high in post-MI survivors with a
mortality rate of 25% at 2 years.[24] Along with prompt
revascularization, optimal medical therapy counteracting nega-
tive cardiac remodeling and implantable cardioverter defibrilla-
tor are mainstay therapies to prevent death in patients with post-
MI LV dysfunction.
Findings of our study contrast with those of a previous study
that did not show a prognostic relevance of PA on the clinical
course of STEMI patients undergoing PPCI.[25] However, there
are several differences between this study and ours that could
explain the conflicting results.
First, we chose as primary endpoint the rate of long-term
cardiac mortality, instead of in-hospital mortality, to better
elucidate the cardiac consequences of PA in STEMI. Second, our
sample size was 4-fold larger than the other one. Finally, patients
of the present studywere enrolled almost a decade later compared
to those of the above mentioned study and had been treated in the
context of current recommended strategies (clopidogrel and new
P2Y12 inhibitors, DES, thrombus aspiration, radial access). Yet,
to our knowledge, this is the first study that evaluates the additive
contribution of PA to the GRACE score in a large unselected
cohort of STEMI patients. We found that although PA
independently stratifies risk of future cardiovascular death, there
is no advantage in adding it to the GRACE score. On the
contrary, we observed a slight worsening of risk classification.5
The study is a prospective analysis of a single-center registry
and it is not immune to sources of bias. Although we tried to
control our results for known prognostic factors by means of
multivariable analysis, the influence of other confounding factors
cannot be ruled out. In particular, we did not collect information
on the presence of collateral flow. However, it is known that in
the context of acute coronary occlusion an efficient collateral
flow is rarely observed. Besides, it has been recently shown that
the presence of collateral flow has no protective role in terms of
infarct size.[7] We did not collect information on LVEF during
follow-up. This is a crucial aspect as it is known that after
coronary revascularization a LV function recovery may occur,
usually within 1 month[26]. Thus, it would have been desirable to
test the association between PA and left ventricle function
recovery in order to provide information on the mechanisms
linking PA and better outcome. In conclusion, in patients with
STEMI undergoing PPCI, the presence of PA is independently
associated with a lower risk of 2-year cardiac mortality.
However, the incorporation of this variable to the GRACE
score slightly worsens the classification of risk. Accordingly, its
utility in clinical practice appears unlikely.Author contributions
Conceptualization: Nevio Taglieri.
Data curation: Gabriele Ghetti, Claudia Rosetti, Paola Battistini,
Gianluca Lanati, Maria Teresa Di Dio, Anna Corsini, Matteo
Bruno, Diego Della Riva, Antonio Giulio Bruno, Miriam
Compagnone, Riccardo Narducci.
Formal analysis: Maria Letizia Bacchi Reggiani, Nevio Taglieri.
Investigation: Gabriele Ghetti, Claudia Rosetti, Paola Battistini,
Gianluca Lanati, Maria Teresa Di Dio, Anna Corsini, Matteo
Bruno, Diego Della Riva, Antonio Giulio Bruno, Miriam
Compagnone, Riccardo Narducci, Nevio Taglieri.
Methodology: Nevio Taglieri.
Supervision: Nevio Taglieri.
Writing – original draft: Gabriele Ghetti.
Writing – review & editing: Francesco Saia, Claudio Rapezzi,
Nevio Taglieri.References
[1] Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the
management of acute myocardial infarction in patients presenting with
ST-segment elevation: The Task Force for the management of acute
myocardial infarction in patients presenting with ST-segment elevation
of the European Society of Cardiology (ESC). Eur Heart J 39;133:
119–77.
[2] Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI
Focused Update on Primary Percutaneous Coronary Intervention for
Patients With ST-Elevation Myocardial Infarction: An Update of the
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Interven-
tion and the 2013 ACCF/AHA Guideline for the Management of ST-
Elevation Myocardial Infarction: A Report of the American College of
Cardiology/American Heart Association Task Force on Clinical Practice
Guidelines and the Society for Cardiovascular Angiography and
Interventions. Circulation 2016;133:1135–47.
[3] Christian TF, Schwartz RS, Gibbons RJ. Determinants of infarct size in
reperfusion therapy for acute myocardial infarction. Circulation
1992;86:81–90.
[4] Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a
delay of lethal cell injury in ischemic myocardium. Circulation 1986;
74:1124–36.
[5] Eisen A, Fisman EZ, RubenfireM, et al. Ischemic preconditioning: nearly
two decades of research. A comprehensive review. Atherosclerosis
2004;172:201–10.
[6] Masci PG, Andreini D, FranconeM, et al. Prodromal angina is associated [17] Kloner RA, Jennings RB. Consequences of brief ischemia: stunning,
Ghetti et al. Medicine (2018) 97:37 Medicinewith myocardial salvage in acute ST-segment elevation myocardial
infarction. Eur Heart J Cardiovasc Imaging 2013;14:1041–8.
[7] Lonborg J, Kelbaek H, Vejlstrup N, et al. Influence of pre-infarction
angina, collateral flow, and pre-procedural TIMI flow on myocardial
salvage index by cardiac magnetic resonance in patients with ST-segment
elevation myocardial infarction. Eur Heart J Cardiovasc Imaging
2012;13:433–43.
[8] Granger CB, Goldberg RJ, Dabbous O, et al. Predictors of hospital
mortality in the global registry of acute coronary events. Arch InternMed
2003;163:2345–53.
[9] Ortolani P, Marzocchi A, Marrozzini C, et al. Clinical impact of direct
referral to primary percutaneous coronary intervention following pre-
hospital diagnosis of ST-elevation myocardial infarction. Eur Heart J
2006;27:1550–7.
[10] Ortolani P, Marzocchi A, Marrozzini C, et al. A. Long-term effectiveness
of early administration of glycoprotein IIb/IIIa agents to real-world
patients undergoing primary percutaneous interventions: results of a
registry study in an ST-elevation myocardial infarction network. Eur
Heart J 2009;30:33–43.
[11] de Winter RJ, Verouden NJ, Wellens HJ, et al. A new ECG sign of
proximal LAD occlusion. N Engl J Med 2008;359:2071–3.
[12] Solomon SD, Anavekar NS, Greaves S, et al. Angina pectoris prior to
myocardial infarction protects against subsequent left ventricular
remodeling. J Am Coll Cardiol 2004;43:1511–4.
[13] Harrell FEJr, Lee KL, Mark DB. Multivariable prognostic models: issues
in developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996;15:361–87.
[14] Demler OV, Paynter NP, Cook NR. Tests of calibration and goodness-
of-fit in the survival setting. Stat Med 2015;34:1659–80.
[15] Pencina MJ, D’Agostino RBSr, Steyerberg EW. Extensions of net
reclassification improvement calculations to measure usefulness of new
biomarkers. Stat Med 2011;30:11–21.
[16] Andreotti F, Pasceri V, Hackett DR, et al. Preinfarction angina as a
predictor of more rapid coronary thrombolysis in patients with acute
myocardial infarction. N Engl J Med 1996;334:7–12.6
preconditioning, and their clinical implications: part 2. Circulation
2001;104:3158–67.
[18] Kloner RA, Jennings RB. Consequences of brief ischemia: stunning,
preconditioning, and their clinical implications: part 1. Circulation
2001;104:2981–9.
[19] Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after
primary percutaneous coronary intervention for acute myocardial
infarction: the CADILLAC risk score. J Am Coll Cardiol 2005;45:
1397–405.
[20] Shiki K, Hearse DJ. Preconditioning of ischemic myocardium: reperfu-
sion-induced arrhythmias. Am J Physiol 1987;253:H1470–6.
[21] Li YW, Whittaker P, Kloner RA. The transient nature of the effect of
ischemic preconditioning on myocardial infarct size and ventricular
arrhythmia. Am Heart J 1992;123:346–53.
[22] Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-
hospital outcome in TIMI 4. A clinical correlate to preconditioning?
Circulation 1995;91:37–45.
[23] Cave AC, Hearse DJ. Ischaemic preconditioning and contractile
function: studies with normothermic and hypothermic global ischaemia.
J Mol Cell Cardiol 1992;24:1113–23.
[24] Raviele A, Bonso A, Gasparini G. Vardas PE, et al.
Prophylactic implantation of implantable cardioverter/defibrillator in
post-myocardial infarction patients. Cardiac Arrhythmias, Pacing and
Electrophysiology Kluger Academic Publishers, Dordrecht:1998;
305–10.
[25] Zahn R, Schiele R, Schneider S, et al. Effect of preinfarction angina
pectoris on outcome in patients with acute myocardial infarction treated
with primary angioplasty (results from the Myocardial Infarction
Registry). Am J Cardiol 2001;87:1–6.
[26] Taglieri N, Saia F, Guiducci V, et al. Left ventricular function after ST-
elevation myocardial infarction in patients treated with primary
percutaneous coronary intervention and abciximab or tirofiban (from
the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
Am J Cardiol 2009;103:785–90.
